SK
Samarth Kumar
Cipla (India), Sun Pharmaceutical Industries Ltd R&D Centre, Maharaja Sayajirao University of Baroda, National Academy of Legal Studies and Research, Aristo Pharmaceuticals Pvt. Ltd.
0009-0009-4023-5684
About
Formulation Development Group Lead for Small & Large Volume Parenterals at SUN PHARMA. Focused on identification, selection, Proof of Concept, unmet needs, differentiation, market needs, value addition and ensuring successful products for InfuSMART® and other platform technologies. Responsible for idea to market (I2M) for SVP & LVP portfolio of Sun Pharmaceutical.
Employment
-
Cipla (India)2025 - Present
-
Sun Pharmaceutical Industries Ltd R&D Centre General Manager R&D2003 - 2025
-
Aristo Pharmaceuticals Pvt. Ltd. RnD Scientist2001 - 2001
-
EROS PHARMA (MICRO LABS limited) Chemist RnD2000 - 2001
Education
-
Maharaja Sayajirao University of Baroda PhD2021 - 2025
-
National Academy of Legal Studies and Research Post Graduate Diploma in PATENT LAW (2nd UNIVERSITY TOPPER)2017 - 2018
-
Rajiv Gandhi Proudyogiki Vishwavidyalaya M. Pharma2001 - 2003
Projects & Funding
Projects & funding information is unavailable.
Publications (237)
- Intravenous infusion dosage form Save
- PARENTERAL DOSAGE FORM OF CARBOPLATIN Save
- PARENTERAL DOSAGE FORM OF CARBOPLATIN Save
- INTRAVENOUS INFUSION DOSAGE FORM COMPRISING PEMETREXED Save
- INTRAVENOUS INFUSION DOSAGE FORM COMPRISING PEMETREXED Save
- INTRAVENØS INFUSIONSDOSERINGSFORM OMFATTENDE PEMETREXED Save
- INTRAVENOUS INFUSION DOSAGE FORM COMPRISING PEMETREXED Save
- Breast cancer: Advances in diagnostic research Save
- Breast cancer: Advances in diagnostic research Save
- Breast cancer: Drug delivery system landscape Save